Evidence map›Paper›PMID 34496841›Full record

ArticleCancer cell international2021

Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma.

Zhen Lin, Yi-Zhao Xie, Ming-Chun Zhao, Pin-Pin Hou, Juan Tang, Guang-Liang Chen

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. New insights into T-cell exhaustion in liver cancer: from mechanism to therapy.Journal of cancer research and clinical oncology · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Zhen Lin *Department of Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Yi-Zhao Xie *Department of Medical Oncology, Fudan University, Shanghai Cancer Center, Shanghai, 200032, China.
Ming-Chun ZhaoDepartment of Pathology, Guilin Hospital of Chinese Traditional and Western Medicine, Guilin, 541004, China.
Pin-Pin HouCentral Laboratory, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201114, China.
Juan TangDepartment of Pathology, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China. juan283tang@163.com.
Guang-Liang ChenDepartment of Medical Oncology, Fudan University, Shanghai Cancer Center, Shanghai, 200032, China. guangliang_chen@fudan.edu.cn.ORCID http://orcid.org/0000-0002-3231-3576
Shanghai Medical College of Fudan University · CNAffiliated Hospital of Guilin Medical College · CNFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGuilin Medical University · CNShanghai Jiao Tong University · CN

Funding

National Natural Science Foundation of China No. 81802362
6 · The paper itself

Abstract

backgroundXanthine dehydrogenase (XDH) is a critical enzyme involved in the oxidative metabolism of purines, pterin and aldehydes and a central component of the innate immune system. However, the prognostic value of XDH in predicting tumor-infiltrating lymphocyte abundance, the immune response, and survival in different cancers, including hepatocellular carcinoma (HCC), is still unclear.

methodsXDH expression was analyzed in multiple databases, including Oncomine, the Tumor Immune Estimation Resource (TIMER), the Kaplan-Meier plotter database, the Gene Expression Profiling Interactive Analysis (GEPIA) database, and The Cancer Genome Atlas (TCGA). XDH-associated transcriptional profiles were detected with an mRNA array, and the levels of infiltrating immune cells were validated by immunohistochemistry (IHC) of HCC tissues. A predictive signature containing multiple XDH-associated immune genes was established using the Cox regression model.

resultsDecreased XDH mRNA expression was detected in human cancers originating from the liver, bladder, breast, colon, bile duct, kidney, and hematolymphoid system. The prognostic potential of XDH mRNA expression was also significant in certain other cancers, including HCC, breast cancer, kidney or bladder carcinoma, gastric cancer, mesothelioma, lung cancer, and ovarian cancer. In HCC, a low XDH mRNA level predicted poorer overall survival, disease-specific survival, disease-free survival, and progression-free survival. The prognostic value of XDH was independent of the clinical features of HCC patients. Indeed, XDH expression in HCC activated several immune-related pathways, including the T cell receptor, PI3K-AKT, and MAPK signaling pathways, which induced a cytotoxic immune response. Importantly, the microenvironment of XDH

conclusionThese findings suggest that XDH is a valuable prognostic biomarker in HCC and other cancers and indicate that it may function in tumor immunology. Loss of XDH expression may be an immune evasion mechanism for HCC.

Indexed as

BiomarkerExhaustion markerHepatocellular carcinomaImmunityXDH

Identifiers

PMID34496841
PMCPMC8425161
OpenAlexW3197307337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.